Details of Disease

General Information of Disease (ID: DIS62RB8)

• Disease Name: Mycosis fungoides
• Synonyms: granuloma fungoides; classic mycosis fungoides; Alibert-Bazin syndrome; mycosis fungoides lymphoma; CTCL/ mycosis fungoides; cutaneous T-cell lymphoma/mycosis fungoides; mycosis fungoides; mycosis fungoides (morphologic abnormality); MF; mycosis fungoides of unspecified site; mycosis fungoides, unspecified site, extranodal and solid organ sites; mycosis fungoides NOS (morphologic abnormality); mycosis fungoides, Alibert-Bazin type
• Disease Class: 2B01: Mycosis fungoides
• Definition: Classical mycosis fungoides is the most common type of mycosis fungoides (MF), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques and eventually to tumors.
• Disease Hierarchy:
  DISWWW80: Mycosis fungoides and variants
  DISAYSZB: Cutaneous T-cell lymphoma
  DIS62RB8: Mycosis fungoides
• ICD Code:
  ICD-11: ICD-11: 2B01
  ICD-10: ICD-10: C84.0
  Expand ICD-11: '2B01
  Expand ICD-10: 'C84.0
• Disease Identifiers:
  MONDO ID: MONDO_0009691
  MESH ID: D009182
  UMLS CUI: C0026948
  OMIM ID: 254400
  MedGen ID: 7771
  Orphanet ID: 2584
  SNOMED CT ID: 118618005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anidulafungin	DM8QM5U	Approved	Small molecular drug	[1]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[2]
Caspofungin	DMGQIPT	Approved	Small molecular drug	[3]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[4]
Cyclophosphamide	DM4O2Z7	Approved	Small molecular drug	[5]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[6]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[7]
Isotretinoin	DM4QTBN	Approved	Small molecular drug	[8]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[9]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[10]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[11]
Mogamulizumab	DMISH0Z	Approved	Monoclonal antibody	[12]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[13]
Prednisone	DM2HG4X	Approved	Small molecular drug	[14]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[15]
Vinblastine	DM5TVS3	Approved	Small molecular drug	[16]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AFM13	DMN45IC	Phase 2	Antibody	[17]
TTI-621	DMDNPAV	Phase 1	Recombinant protein	[18]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 23 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CXCL11	TTWG0RE	Limited	Biomarker	[19]
IL16	TTW4R0B	Limited	Altered Expression	[20]
KIR3DL2	TTQH3N0	Limited	Altered Expression	[21]
USP2	TTUEQ1W	Disputed	Altered Expression	[22]
CCL21	TTLZK1U	Strong	Biomarker	[23]
CCR4	TT7HQD0	Strong	Biomarker	[24]
CD28	TTQ13FT	Strong	FusionGene	[25]
CD7	TTP6B8O	Strong	Biomarker	[26]
CTLA4	TTI2S1D	Strong	FusionGene	[25]
DPP4	TTDIGC1	Strong	Altered Expression	[27]
HLA-DQB2	TTL7VOU	Strong	Genetic Variation	[28]
IL31	TT1RJXK	Strong	Biomarker	[29]
IL32	TTD4G7L	Strong	Biomarker	[30]
KLK5	TTULSEW	Strong	Altered Expression	[31]
RNF34	TTEWDK1	Strong	Genetic Variation	[32]
SELPLG	TTS5K8U	Strong	Biomarker	[33]
TCIRG1	TTVRN05	Strong	Altered Expression	[34]
TCL1A	TTUKRDV	Strong	Altered Expression	[35]
TNFRSF1B	TT63WSF	Strong	Genetic Variation	[36]
TRB	TT84HCW	Strong	Genetic Variation	[37]
TRBC1	TT1DHW2	Strong	Genetic Variation	[37]
USP14	TTVSYP9	Strong	Biomarker	[38]
ZNF217	TTY3BRA	Strong	Biomarker	[39]

This Disease Is Related to 37 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCL27	OTUZYC61	Limited	Altered Expression	[40]
CCR10	OT7ZWSSD	Limited	Biomarker	[40]
GNG8	OT9YHSF1	Limited	Genetic Variation	[41]
HM13	OTGEO1LP	Limited	Biomarker	[42]
KRT1	OTIOJWA4	Limited	Altered Expression	[43]
NFKBIZ	OTU728KS	Limited	Altered Expression	[44]
NKG7	OTXDD006	Limited	Altered Expression	[45]
TRIP13	OTFM3TI9	Limited	Biomarker	[44]
SOX18	OTPUMHWA	Disputed	Biomarker	[46]
ACSBG1	OTM040MW	Strong	Genetic Variation	[47]
BCL7A	OTYFUJTP	Strong	Genetic Variation	[48]
CADM1	OTRWG9QS	Strong	Altered Expression	[49]
CDO1	OTLG1P77	Strong	Altered Expression	[50]
DEFB103B	OT8RWY64	Strong	Altered Expression	[51]
DNM3	OTDMUGCR	Strong	Altered Expression	[50]
DUSP22	OTEZ3U85	Strong	Genetic Variation	[52]
HBD	OTRQG4WA	Strong	Altered Expression	[51]
HELLS	OTVVV668	Strong	Biomarker	[53]
HHEX	OTLIUVYX	Strong	Biomarker	[53]
ICAM3	OTTZ5A5D	Strong	Biomarker	[54]
INTS1	OT7TY1M1	Strong	Genetic Variation	[55]
INTS2	OT2N5TCK	Strong	Biomarker	[55]
MYBL2	OTZ3JX8Q	Strong	Biomarker	[39]
MYCL	OT1MFQ5U	Strong	Biomarker	[39]
NAV3	OT97M1TR	Strong	Genetic Variation	[36]
PLA2G4D	OTKBAB0F	Strong	Altered Expression	[56]
PWWP3A	OTXQVL4U	Strong	Altered Expression	[52]
QTRT1	OTC33MCV	Strong	Biomarker	[38]
RAPH1	OTMQXW7S	Strong	Genetic Variation	[47]
RHOF	OTPA3F8Q	Strong	Genetic Variation	[48]
SHARPIN	OTU1J2KH	Strong	Altered Expression	[57]
SS18	OTDKHN1E	Strong	Biomarker	[58]
STAT4	OTAK3VFR	Strong	Altered Expression	[59]
TCL1B	OT4CSO39	Strong	Altered Expression	[35]
TOX	OTE8BL5Z	Strong	Altered Expression	[60]
TSPYL2	OTGGW2EF	Strong	Biomarker	[61]
BCL11B	OT8KKCVJ	Definitive	Altered Expression	[62]

References

• [1] Anidulafungin FDA Label
• [2] Betamethasone FDA Label
• [3] Caspofungin FDA Label
• [4] Cortisone acetate FDA Label
• [5] Cyclophosphamide FDA Label
• [6] Dexamethasone FDA Label
• [7] Hydrocortisone FDA Label
• [8] Isotretinoin FDA Label
• [9] Mechlorethamine FDA Label
• [10] Methotrexate FDA Label
• [11] Methylprednisolone FDA Label
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Prednisolone FDA Label
• [14] Prednisone FDA Label
• [15] Triamcinolone FDA Label
• [16] Vinblastine FDA Label
• [17] ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.J Dermatol Sci. 2016 Sep;83(3):182-9. doi: 10.1016/j.jdermsci.2016.05.004. Epub 2016 Jun 8.
• [20] IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.Exp Dermatol. 2000 Aug;9(4):248-51. doi: 10.1034/j.1600-0625.2000.009004248.x.
• [21] Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Szary syndrome.Best Pract Res Clin Haematol. 2019 Sep;32(3):239-252. doi: 10.1016/j.beha.2019.06.004. Epub 2019 Jun 6.
• [22] Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.Oncotarget. 2016 Jul 26;7(30):48391-48400. doi: 10.18632/oncotarget.10268.
• [23] CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma.In Vivo. 2019 May-Jun;33(3):793-800. doi: 10.21873/invivo.11541.
• [24] C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.Histopathology. 2020 Jan;76(2):222-232. doi: 10.1111/his.13960. Epub 2019 Nov 13.
• [25] Genomic analysis of mycosis fungoides and Szary syndrome identifies recurrent alterations in TNFR2.Nat Genet. 2015 Sep;47(9):1056-60. doi: 10.1038/ng.3370. Epub 2015 Aug 10.
• [26] Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation.J Am Acad Dermatol. 1986 Jun;14(6):1006-13. doi: 10.1016/s0190-9622(86)70124-2.
• [27] Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders.Cytometry B Clin Cytom. 2019 Jul;96(4):283-293. doi: 10.1002/cyto.b.21784. Epub 2019 May 3.
• [28] Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system.J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):393-402. doi: 10.1016/j.jaad.2003.12.052.
• [29] Analysis of the IL-31 pathway in Mycosis fungoides and Szary syndrome.Arch Dermatol Res. 2015 Aug;307(6):479-85. doi: 10.1007/s00403-014-1527-x. Epub 2014 Dec 7.
• [30] IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: Relevance to mycosis fungoides progression.Oncoimmunology. 2016 May 5;6(2):e1181237. doi: 10.1080/2162402X.2016.1181237. eCollection 2017.
• [31] Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression.Eur J Dermatol. 2019 Jun 1;29(3):268-273. doi: 10.1684/ejd.2019.3560.
• [32] Maintenance phase in psoralen-ultraviolet A phototherapy of early-stage mycosis fungoides. Acritically appraised topic.Br J Dermatol. 2017 Aug;177(2):406-410. doi: 10.1111/bjd.15302.
• [33] Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides.Anal Quant Cytol Histol. 2008 Aug;30(4):203-8.
• [34] Genetic Analysis of Giant Cell Lesions of the Maxillofacial and Axial/Appendicular Skeletons.J Oral Maxillofac Surg. 2017 Feb;75(2):298-308. doi: 10.1016/j.joms.2016.07.014. Epub 2016 Jul 26.
• [35] Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.Cancer Res. 2000 Apr 15;60(8):2095-100.
• [36] Analysis of differential variable region of T cell receptor expression and NAV3/TNFRSF1B gene mutation in mycosis fungoides.Oncotarget. 2016 Apr 5;7(14):17986-90. doi: 10.18632/oncotarget.7673.
• [37] Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides.Clin Cancer Res. 2020 Jan 15;26(2):408-418. doi: 10.1158/1078-0432.CCR-18-4147. Epub 2019 Oct 21.
• [38] K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose.Environ Mol Mutagen. 2010 Mar;51(2):146-55. doi: 10.1002/em.20513.
• [39] Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.Blood. 2003 Feb 15;101(4):1513-9. doi: 10.1182/blood-2002-08-2434. Epub 2002 Oct 3.
• [40] Microarray analysis of gene expression by microdissected epidermis and dermis in mycosis fungoides and adult T-cell leukemia/lymphoma.Int J Oncol. 2014 Sep;45(3):1200-8. doi: 10.3892/ijo.2014.2524. Epub 2014 Jun 26.
• [41] Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas.Am J Pathol. 1997 Jun;150(6):1941-9.
• [42] Expression of cancer/testis antigens in cutaneous T cell lymphomas.Int J Cancer. 2002 Feb 10;97(5):668-70. doi: 10.1002/ijc.1643.
• [43] Differential expression of CRABP II, psoriasin and cytokeratin 1 mRNA in human skin diseases.Arch Dermatol Res. 1996 Jul;288(8):426-30. doi: 10.1007/BF02505229.
• [44] A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.J Invest Dermatol. 2012 Aug;132(8):2050-9. doi: 10.1038/jid.2012.117. Epub 2012 Apr 19.
• [45] Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.Clin Cancer Res. 2006 Aug 15;12(16):4812-21. doi: 10.1158/1078-0432.CCR-06-0532.
• [46] Expression of SOX18 in Mycosis Fungoides.Acta Derm Venereol. 2017 Jan 4;97(1):17-23. doi: 10.2340/00015555-2466.
• [47] Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.Am J Surg Pathol. 2012 May;36(5):716-25. doi: 10.1097/PAS.0b013e3182487158.
• [48] Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF.Genes Chromosomes Cancer. 2008 Dec;47(12):1067-75. doi: 10.1002/gcc.20601.
• [49] The expression of cell adhesion molecule 1 and its splicing variants in Szary cells and cell lines from cutaneous T-cell lymphoma.J Dermatol. 2019 Nov;46(11):967-977. doi: 10.1111/1346-8138.15078. Epub 2019 Sep 12.
• [50] Szary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.Leukemia. 2008 Feb;22(2):393-9. doi: 10.1038/sj.leu.2405044. Epub 2007 Nov 22.
• [51] Expression of human beta-defensins in patients with mycosis fungoides.Arch Dermatol Res. 2007 Jul;299(4):221-4. doi: 10.1007/s00403-007-0749-6. Epub 2007 Apr 6.
• [52] Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression.Pathology. 2018 Dec;50(7):718-724. doi: 10.1016/j.pathol.2018.08.008. Epub 2018 Oct 20.
• [53] Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome: identification of two discrete regions of deletion at 10q23.33-24.1 and 10q24.33-25.1.Genes Chromosomes Cancer. 2005 Feb;42(2):184-92. doi: 10.1002/gcc.20115.
• [54] CD20 positive mycosis fungoides: a case report.J Cutan Pathol. 2008 Apr;35(4):398-403. doi: 10.1111/j.1600-0560.2007.00817.x. Epub 2008 Feb 4.
• [55] Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.
• [56] Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin.J Biol Chem. 2004 Mar 26;279(13):12890-7. doi: 10.1074/jbc.M305801200. Epub 2004 Jan 6.
• [57] SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-B pathway in Mycosis Fungoides.Exp Dermatol. 2019 Nov;28(11):1279-1288. doi: 10.1111/exd.14026. Epub 2019 Sep 10.
• [58] Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation.J Invest Dermatol. 2008 Oct;128(10):2458-66. doi: 10.1038/jid.2008.113. Epub 2008 May 29.
• [59] Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.Cell Cycle. 2014;13(18):2975-82. doi: 10.4161/15384101.2014.947759.
• [60] Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.Arch Dermatol Res. 2020 Sep;312(7):513-525. doi: 10.1007/s00403-019-02000-0. Epub 2019 Nov 1.
• [61] Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.Tumori. 2018 Oct;104(5):394-400. doi: 10.5301/tj.5000606. Epub 2018 May 8.
• [62] BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.J Invest Dermatol. 2017 Jul;137(7):1523-1532. doi: 10.1016/j.jid.2017.02.980. Epub 2017 Mar 10.